The eosinophil-depleting monoclonal antibody benralizumab didn't cut acute exacerbations in eosinophilic chronic obstructive pulmonary disease (COPD) in an early phase study.
But a secondary endpoint suggested some benefit in terms of lung function from the anti-interleukin (IL) 5 receptor drug, the group reported online in Lancet Respiratory Medicine in conjunction with presentation at the European Respiratory Society meeting in Munich.
Also read: FDA OKs 2nd gene therapy for blood cancer; 1st for adults
Read more